Universe Pharmaceuticals INC (UPC)

UPC Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Revenue	23.02	32.31	40.14	47.98	30.7
Revenue Growth (YoY)	-28.74%	-19.52%	-16.34%	56.27%	-7.60%
Cost of Revenue	16.95	21.99	18.25	22.66	16.61
Gross Profit	6.07	10.32	21.89	25.33	14.09
Selling, General & Admin	11.06	9.33	21.27	6.17	3.16
Research & Development	3.03	4.86	7.64	5.47	0.58
Other Operating Expenses	0	0.1	-	0.1	0.1
Operating Expenses	14.09	14.28	28.91	11.74	3.84
Operating Income	-8.02	-3.97	-7.02	13.59	10.25
Interest Expense	-0.3	-0.19	-0.2	-0.15	-0.16
Interest & Investment Income	0.03	0.03	0.04	0.29	0.03
Earnings From Equity Investments	0.03	0.03	0.04	0.03	0.02
Other Non Operating Income (Expenses)	0.15	-0.24	0.05	-0.08	-0.05
EBT Excluding Unusual Items	-8.12	-4.33	-7.09	13.68	10.1
Gain (Loss) on Sale of Assets	-0	-0	-0	-0	-
Pretax Income	-8.12	-4.33	-7.09	13.68	10.1
Income Tax Expense	0.61	2.25	0.82	2.36	2.54
Net Income	-8.73	-6.58	-7.91	11.32	7.56
Net Income to Common	-8.73	-6.58	-7.91	11.32	7.56
Net Income Growth	-	-	-	49.77%	0.09%
Shares Outstanding (Basic)	0	-	-	-	-
Shares Outstanding (Diluted)	0	-	-	-	-
EPS (Basic)	-626.96	-	-	-	-
EPS (Diluted)	-626.96	-	-	-	-
Free Cash Flow	-9.75	1.07	-1.39	-15.59	6.06
Free Cash Flow Per Share	-700.61	-	-	-	-
Gross Margin	26.37%	31.93%	54.53%	52.78%	45.90%
Operating Margin	-34.83%	-12.28%	-17.49%	28.32%	33.39%
Profit Margin	-37.90%	-20.37%	-19.70%	23.59%	24.62%
Free Cash Flow Margin	-42.36%	3.32%	-3.47%	-32.48%	19.75%
EBITDA	-7.53	-3.46	-6.49	14.04	10.66
EBITDA Margin	-32.72%	-10.70%	-16.16%	29.25%	34.73%
D&A For EBITDA	0.49	0.51	0.53	0.45	0.41
EBIT	-8.02	-3.97	-7.02	13.59	10.25
EBIT Margin	-34.83%	-12.28%	-17.49%	28.32%	33.39%
Effective Tax Rate	-	-	-	17.24%	25.17%
Advertising Expenses	5.27	4.76	-	1.33	0.36

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q